CenExel Appoints Dr. Sy Pretorius as Chief Executive Officer

Pretorius brings extensive experience leading pharmaceutical organizations

Apr. 7, 2026 at 7:08pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of medical research documents, a pen, and a pair of reading glasses arranged elegantly on a clean, white seamless background, conceptually representing the abstract concepts of pharmaceutical strategy and medical innovation.The appointment of a seasoned pharmaceutical executive signals CenExel's commitment to innovation in the clinical research industry.Draper Today

CenExel Clinical Research, a leading clinical research site network, has announced the appointment of Dr. Sy Pretorius as its new Chief Executive Officer. Pretorius is a seasoned executive with a proven track record of leading large pharmaceutical organizations.

Why it matters

CenExel is a major player in the clinical research industry, conducting trials for some of the world's largest pharmaceutical companies. Pretorius' appointment signals the company's commitment to growth and innovation as it navigates the evolving healthcare landscape.

The details

Dr. Sy Pretorius has been named the new Chief Executive Officer of CenExel Clinical Research, a leading clinical research site network. Pretorius brings extensive experience leading scaled pharmaceutical organizations and will be responsible for driving CenExel's strategic vision and operational excellence.

  • CenExel announced Pretorius' appointment on April 7, 2026.

The players

CenExel Clinical Research

A leading, wholly-owned clinical research site network.

Dr. Sy Pretorius

The newly appointed Chief Executive Officer of CenExel Clinical Research, with a proven track record of leading large pharmaceutical organizations.

Got photos? Submit your photos here. ›

The takeaway

Pretorius' appointment as CEO of CenExel signals the company's commitment to growth and innovation in the clinical research industry, as it looks to leverage his extensive experience leading large pharmaceutical organizations.